1-3 of 3
Laura Cannella, MD
Close
Sort by
Journal Articles

Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation

Alessandro Sanna, MD, Laura Cannella, MD, Antonella Gozzini, MD, Massimo Breccia, MD, Francesca Sassolini, MD, Alberto Bosi, MD, Giuliana Alimena, MD, Valeria Santini, MD
Journal: Blood
Blood (2010) 116 (21): 606.
https://doi.org/10.1182/blood.V116.21.606.606
Published: 2010
Journal Articles

Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).

Massimo Breccia, MD, Roberto Latagliata, MD, Laura Cannella, MD, Ida Carmosino, MD, Enrico Gottardi, Daniela Cilloni, MD, Marco Vignetti, MD, Michelina Santopietro, MD, Marco Mancini, MD, Giuliana Alimena, MD
Journal: Blood
Blood (2009) 114 (22): 1777.
https://doi.org/10.1182/blood.V114.22.1777.1777
Published: 2009
Journal Articles

Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 EuropeanLeukemia Net (ELN) Criteria.

Massimo Breccia, MD, Fabio Stagno, MD, Roberto Latagliata, MD, Paolo Vigneri, MD, Laura Cannella, MD, Ida Carmosino, MD, Vittorio Del Fabro, MD, Francesco Di Raimondo, MD, Giuliana Alimena, MD
Journal: Blood
Blood (2009) 114 (22): 3302.
https://doi.org/10.1182/blood.V114.22.3302.3302
Published: 2009